New drug frexalimab aims to outperform tacrolimus in kidney transplants
NCT ID NCT07412470
First seen Feb 19, 2026 · Last updated Jun 20, 2026 · Updated 15 times
Summary
This study tests whether the drug frexalimab can prevent kidney transplant rejection better than the standard drug tacrolimus. About 526 adults receiving their first kidney transplant will be randomly assigned to one of the two treatments and followed for up to 5 years. The main goal is to see if frexalimab reduces the combined risk of rejection, graft loss, or death within the first year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT REJECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Study site
RECRUITINGTorette, Ancona, 60020, Italy
-
Investigational Site Number : 0320001
RECRUITINGCorrientes, 3400, Argentina
-
Investigational Site Number : 0360001
RECRUITINGParkville, Victoria, 3050, Australia
-
Investigational Site Number : 0360002
RECRUITINGAdelaide, South Australia, 5000, Australia
-
Investigational Site Number : 0360003
RECRUITINGSydney, 2050, Australia
-
Investigational Site Number : 1520004
RECRUITINGSantiago, Reg Metropolitana de Santiago, 8330034, Chile
-
Investigational Site Number : 1520005
RECRUITINGSantiago, Reg Metropolitana de Santiago, 8320325, Chile
-
Investigational Site Number : 1560001
RECRUITINGShanghai, 200127, China
-
Investigational Site Number : 1560003
RECRUITINGChengdu, 610041, China
-
Investigational Site Number : 1560005
RECRUITINGZhengzhou, 450052, China
-
Investigational Site Number : 1560006
RECRUITINGWuhan, 430030, China
-
Investigational Site Number : 1560008
RECRUITINGNanning, 530007, China
-
Investigational Site Number : 1560009
RECRUITINGZhengzhou, 450061, China
-
Investigational Site Number : 1560012
RECRUITINGJinan, 250014, China
-
Investigational Site Number : 1560017
RECRUITINGNanchang, 330006, China
-
Investigational Site Number : 2080001
RECRUITINGAarhus, 8200, Denmark
-
Investigational Site Number : 3760002
RECRUITINGRamat Gan, 5262100, Israel
-
Investigational Site Number : 7240001
RECRUITINGBarcelona, Barcelona [Barcelona], 08035, Spain
-
Investigational Site Number : 7240003
RECRUITINGL'Hospitalet de Llobregat, Catalunya [Cataluña], 08907, Spain
-
Investigational Site Number : 7240005
RECRUITINGMálaga, 29010, Spain
-
Investigational Site Number : 7240007
RECRUITINGBarcelona, Catalunya [Cataluña], 08036, Spain
-
Investigational Site Number : 8260001
RECRUITINGBirmingham, England, B15 2TH, United Kingdom
-
Montefiore Medical Center - Moses Campus- Site Number : 8400006
RECRUITINGThe Bronx, New York, 10467, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
frexalimab
What this could lead to
If successful, frexalimab could offer a new option to prevent kidney transplant rejection, potentially with fewer side effects than current standard treatments.
What could go wrong
This is an early-to-mid-stage trial (phase 2/3) with 526 participants, so results may not confirm long-term safety or effectiveness. Open-label design may introduce bias.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.